1. Home
  2. EHTH vs MREO Comparison

EHTH vs MREO Comparison

Compare EHTH & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo eHealth Inc.

EHTH

eHealth Inc.

N/A

Current Price

$1.24

Market Cap

46.0M

Sector

Finance

ML Signal

N/A

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

N/A

Current Price

$0.30

Market Cap

50.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EHTH
MREO
Founded
1997
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.0M
50.3M
IPO Year
2006
2017

Fundamental Metrics

Financial Performance
Metric
EHTH
MREO
Price
$1.24
$0.30
Analyst Decision
Hold
Buy
Analyst Count
3
5
Target Price
$3.33
$1.50
AVG Volume (30 Days)
219.7K
4.9M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
71.43
16.67
EPS
N/A
N/A
Revenue
$251,395,000.00
$500,000.00
Revenue This Year
N/A
$5,184.20
Revenue Next Year
$5.60
$55.51
P/E Ratio
N/A
N/A
Revenue Growth
45.86
N/A
52 Week Low
$1.19
$0.20
52 Week High
$5.89
$2.37

Technical Indicators

Market Signals
Indicator
EHTH
MREO
Relative Strength Index (RSI) 40.89 45.51
Support Level $1.21 $0.28
Resistance Level $1.55 $0.35
Average True Range (ATR) 0.08 0.03
MACD 0.00 -0.00
Stochastic Oscillator 14.75 28.17

Price Performance

Historical Comparison
EHTH
MREO

About EHTH eHealth Inc.

eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is derived from the United States. It also has a presence in China.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: